Journal of Neuroimmune Pharmacology

, Volume 1, Issue 3, pp 260–269 | Cite as

Opioid Receptors and Signaling on Cells from the Immune System

  • Jean M. Bidlack
  • Maxim Khimich
  • Amy L. Parkhill
  • Sarah Sumagin
  • Baoyong Sun
  • Christopher M. Tipton
Invited Review

Abstract

This review discusses the criteria for determining whether a binding site or functional response is directly mediated by either the mu, delta, or kappa opioid receptors. In 1988, Sibinga and Goldstein published the first review that addressed whether cells from the immune system express opioid receptors. The criteria that they used, namely, structure–activity relationships, stereoselectivity, dose- and concentration-dependence, and saturability are still relevant criteria today for determining if an immunological response is mediated by either the mu, delta or kappa opioid receptors. Radioligand receptor binding studies and functional studies that clearly show the presence of an opioid receptor on immunocytes are presented. Selective agonists and antagonists for the mu, delta, and kappa opioid receptors are discussed, and the need for their use in experiments is emphasized. Conditions used in functional assays are very important. Receptor desensitization and downregulation occur within minutes after the application of an agonist. However, many immunological assays are applying an agonist for days before measuring an immunological effect. The results obtained may reflect changes that are results of receptor desensitization and/or downregulation instead of changes that are observed with acute activation of the receptor. The future of receptor pharmacology lies in the crosstalk and dimerization of G protein-coupled receptors. In transfected systems, opioid receptors have been shown to dimerize with chemokine and cannabinoid receptors, resulting in crosstalk between different types of receptors.

Key words

opioid receptors immune chemokine receptors selective opioids receptor dimerization mu, delta and kappa opioid receptors 

Notes

Acknowledgements

This work was supported by grants K05-DA00360 and DA04355.

References

  1. Alicea C, Belkowski SM, Sliker JK, Zhu J, Liu-Chen LY, Eisenstein TK, Adler MW, Rogers TJ (1998) Characterization of kappa-opioid receptor transcripts expressed by T cells and macrophages. J Neuroimmunol 91:55–62PubMedGoogle Scholar
  2. Apte RN, Durum SK, Oppenheim JJ (1990) Opioids modulate interleukin-1 production and secretion by bone-marrow macrophages. Immunol Lett 24:141–148PubMedGoogle Scholar
  3. Bayer BM, Daussin S, Hernandez M, Irvin L (1990) Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 29:369–374PubMedGoogle Scholar
  4. Bayer BM, Gastonguay MR, Hernandez MC (1992) Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist selectivity and naltrexone reversiblity. Immunopharmacology 23:117–124PubMedGoogle Scholar
  5. Belkowski SM, Alicea C, Eisenstein TK, Adler MW, Rogers TJ (1995a) Inhibition of interleukin-1 and tumor necrosis factor-α synthesis following treatment of macrophages with the kappa opioid agonist U50,488H. J Pharmacol Exp Ther 273:1491–1496PubMedGoogle Scholar
  6. Belkowski SM, Zhu JM, Liu-Chen L-Y, Eisenstein TK, Adler MW, Rogers TJ (1995b) Sequence of kappa-opioid receptor cDNA in the R1.1 thymoma cell line. J Neuroimmunol 62:113–117PubMedGoogle Scholar
  7. Belkowski SM, Zhu J, Liu-Chen L-Y, Eisenstein TK, Adler MW, Rogers TJ (1995c) Detection of kappa-opioid receptor mRNA in immature T-cells. Adv Exp Med Biol 373:11–16PubMedGoogle Scholar
  8. Bidlack JM (2000) Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol 7:719–723PubMedGoogle Scholar
  9. Bidlack JM, Abraham MK (2001) Mitogen-induced activation of mouse T cells increases kappa opioid receptor expression. Adv Exp Med Biol 493:103–110PubMedGoogle Scholar
  10. Bidlack JM, Saripalli LD, Lawrence DMP (1992) κ-Opioid binding sites on a murine lymphoma cell line. Eur J Pharmacol 227:257–265PubMedGoogle Scholar
  11. Bilsky EJ, Calderon SN, Wang T, Bernstein RN, Davis P, Hruby VJ, McNutt RW, Rothman RB, Rice KC, Porreca F (1995) SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J Pharmacol Exp Ther 273:359–366PubMedGoogle Scholar
  12. Börner C, Höllt V, Kraus J (2006) Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells. Mol Pharmacol 69:1486–1491PubMedGoogle Scholar
  13. Boyadjieva NI, Chaturvedi K, Poplawski MM, Sarkar DK (2004) Opioid antagonist naltrexone disrupts feedback interaction between mu and delta opioid receptors in splenocytes to prevent alcohol inhibition of NK cell function. J Immunol 173:42–49PubMedGoogle Scholar
  14. Bryant HU, Bernton EW, Holaday JW (1987) Immunosuppressive effects of chronic morphine treatment in mice. Life Sci 41:1731–1738PubMedGoogle Scholar
  15. Bryant HU, Bernton EW, Kenner JR, Holaday JW (1991) Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment. Endocrinology 128:3253–3258PubMedGoogle Scholar
  16. Calderon SN, Rothman RB, Porreca F, Flippen-Anderson JL, McNutt RW, Xu H, Smith, LE, Bilsky EJ, Davis P, Rice KC (1994) Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. J Med Chem 37:2125–2128PubMedGoogle Scholar
  17. Caroleo MC, Arbitrio M, Melchiorri D, Nistico G (1994) A reappraisal of the role of the various opioid receptor subtypes in cell-mediated immunity. Neuroimmunomodulation 1:141–147PubMedGoogle Scholar
  18. Carr DJJ, DeCosta BR, Kim C-H, Jacobson AE, Guarcello V, Rice KC, Blalock JE (1989) Opioid receptors on cells of the immune system: evidence for δ- and κ-classes. J Endocrinol 122:161–168PubMedCrossRefGoogle Scholar
  19. Carrigan KA, Saurer TB, Ijames SG, Lysle DT (2004) Buprenorphine produces naltrexone reversible alterations of immune status. Int Immunopharmacol 4:419–428PubMedGoogle Scholar
  20. Chang SL, Moldow RL, House SD, Zadina JE (1996) Morphine affects the brain-immune axis by modulating an interleukin-1 beta dependent pathway. Adv Exp Med Biol 402:35–42PubMedGoogle Scholar
  21. Chao CC, Sharp BM, Pomeroy C, Filice GA, Peterson PK (1990) Lethality of morphine in mice infected with Toxoplasma gondii. J Pharmacol Exp Ther 252:605–609PubMedGoogle Scholar
  22. Chao CC, Gekker G, Hu S, Sheng WS, Portoghese PS, Peterson PK (1995) Upregulation of HIV-1 expression in co-cultures of chronically infected promonocytes and human brain cells by dynorphin. Biochem Pharmacol 50:715–722PubMedGoogle Scholar
  23. Chao CC, Gekker G, Hu S, Sheng WS, Bu D-F, Archer S, Bidlack JM, Peterson PK (1996) Kappa opioid receptors in human microglia downregulate human immunodeficiency virus-1 expression. Proc Natl Acad Sci USA 93:8051–8056PubMedGoogle Scholar
  24. Chen Y, Mestek A, Liu J, Hurley JA, Yu L (1993) Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44:8–12PubMedGoogle Scholar
  25. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen L-Y (2004) Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 483:175–186PubMedGoogle Scholar
  26. Chuang LF, Chuang TK, Killam KF Jr, Chuang AJ, Kung H, Yu L, Chuang RY (1994) Delta opioid receptor gene expression in lymphocytes. Biochem Biophys Res Commun 202:1291–1299PubMedGoogle Scholar
  27. Chuang LF, Chuang TK, Killam KF Jr, Qui Q, Wang XR, Lin JJ, Kung HF, Sheng W, Chao C, Yu L, Chuang RY (1995a) Expression of kappa opioid receptors in human and monkey lymphocytes. Biochem Biophys Res Commun 209:1003–1010Google Scholar
  28. Chuang TK, Killam KF Jr, Chuang LF, Kung HF, Sheng WS, Chao CC, Yu L, Chuang RY (1995b) Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun 216:922–930Google Scholar
  29. Eisenstein TK, Hilburger ME (1998) Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmumol 83:36–44Google Scholar
  30. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH (1992) Cloning of a delta opioid receptor by functional expression. Science 258:1952–1955PubMedGoogle Scholar
  31. Fecho K, Dykstra LA, Lysle DT (1993) Evidence for β-adrenergic receptor involvement in the immunomodulatory effects of morphine. J Pharmacol Exp Ther 265:1079–1087PubMedGoogle Scholar
  32. Fiorica E, Spector S (1988) Opioid binding site in EL-4 thymoma cell line. Life Sci 42:199–206PubMedGoogle Scholar
  33. Foris G, Medgyesi GA, Nagy JT, Varga Z (1987) Concentration-dependent effect of met-enkephalin on human polymorphonuclear leukocytes. Ann NY Acad Sci 496:51–157Google Scholar
  34. Foster JS, Moore RN (1987) Dynorphin and related opioid peptides enhance tumoricidal activity mediated by murine peritoneal macrophages. J Leuk Biol 42:171–174Google Scholar
  35. Gavériaux C, Peluso J, Simonin F, LaForet J, Kieffer B (1995) Identification of kappa- and delta-opioid receptor transcripts in immune cells. FEBS Lett 369:272–276PubMedGoogle Scholar
  36. Gavériaux-Ruff C, Peluso J, Befort K, Simonin F, Zilliox C, Kieffer BL (1997) Detection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the delta- and kappa-opioid receptors. Mol Brain Res 48:298–304PubMedGoogle Scholar
  37. Gavériaux-Ruff C, Simonin, F, Filliol, D, Kieffer BL (2003) Enhanced humoral response in kappa-opioid receptor knockout mice. J Neuroimmunol 134:72–81PubMedGoogle Scholar
  38. Guan L, Townsend R, Eisenstein TK, Adler MW, Rogers TK (1994) Both T-cells and macrophages are target of κ-opioid-induced immunosuppression. Brain Behav Immun 8:229–240PubMedGoogle Scholar
  39. Guan L, Eisenstein TK, Adler MW, Rogers TJ (1997) Inhibition of T cell superantigen responses following treatment with the kappa-opioid agonist U50,488H. J Neuroimmunol 75:163–168PubMedGoogle Scholar
  40. Gulya K, Liu GK, Pelton JT, Kazmierski W, Hruby VJ, Yamamura HI. (1986) H-d-Phe-Cys-Tyr-d-Trp-Orn-Thr-Pen-Thr-NH2: a potent and selective antagonist opioid receptors. NIDA Res Monogr 75:209–212PubMedGoogle Scholar
  41. Gungor M, Genc E, Sogduyu H, Eroglu L, Koyuncuoglu H (1980) Effect of chronic administration of morphine on primary immune response in mice. Experientia 36:1309–1310PubMedGoogle Scholar
  42. Gunji N, Nagashima M, Asano G, Yoshino S (2000) Expression of kappa-opioid receptor mRNA in human peripheral blood lymphocytes and the relationship between its expression and the inflammatory changes in rheumatoid arthritis. Rheumatol Int 19:95–100PubMedGoogle Scholar
  43. Hagi K, Uno K, Inaba K, Muramatsu S (1994) Augmenting effect of opioid peptides on murine macrophage activation. J Neuroimmunol 50:71–76PubMedGoogle Scholar
  44. Heagy W, Laurance M, Cohen E, Finberg R (1990) Neurohormones regulate T-cell function. J Exp Med 171:1625–1633PubMedGoogle Scholar
  45. Ignatowski TA, Bidlack JM (1998) Detection of kappa opioid receptors on mouse thymocyte phenotypic subpopulations as assessed by flow cytometry. J Pharmacol Exp Ther 284:298–306PubMedGoogle Scholar
  46. Ignatowski TA, Bidlack JM (1999) Differential κ-opioid receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation. J Pharmacol Exp Ther 290:863–870PubMedGoogle Scholar
  47. Khimich M, Bidlack JM (2005) Kappa-opioid induced IL-7 receptor mRNA expression in R1.1 thymoma cell line. Society on NeuroImmune Pharmacology Meeting, Clearwater Beach, Florida, April 6–9, 2005Google Scholar
  48. Klein TW, Cabral GA (2006) Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 1:50–64PubMedGoogle Scholar
  49. Lawrence DMP, Bidlack JM (1992) Kappa opioid binding sites on the R1.1 murine lymphoma cell line: sensitivity to cations and guanine nucleotides. J Neuroimmunol 41:223–230PubMedGoogle Scholar
  50. Lawrence DMP, Bidlack JM (1993) The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding protein. J Pharmacol Exp Ther 266:1678–1683PubMedGoogle Scholar
  51. Lawrence DMP, El-Hamouly W, Archer S, Leary JF, Bidlack JM (1995a) Identification of κ opioid receptors in the immune system by indirect immunofluorescence. Proc Natl Acad Sci USA 92:1062–1066PubMedGoogle Scholar
  52. Lawrence DMP, Joseph DB, Bidlack JM (1995b) Kappa opioid receptors expressed on three related thymoma cell lines. Differences in receptor–effector coupling. Biochem Pharmacol 49:81–89PubMedGoogle Scholar
  53. Lefkowiz SS, Chiang CY (1975) Effects of certain abused drugs on hemolysin forming cells. Life Sci 17:1763–1768Google Scholar
  54. Lewis JW (1995). Clinical pharmacology of buprenorphine in relation to its use as an analgesic. In: Cowan A, Lewis JW (eds) Buprenorphine: combating drug abuse with a unique opioid. Wiley-Liss, New York, pp 151–163Google Scholar
  55. Li S, Zhu J, Chen C, Chen Y-W, DeRiel JK, Ashby B, Liu-Chen L-Y (1993) Molecular cloning and expression of a rat kappa opioid receptor. Biochem J 295:629–633PubMedGoogle Scholar
  56. Li MD, McAllen K, Sharp BM (1999) Regulation of delta opioid receptor expression by anti-CD3-ɛ, PMA, and ionomycin in murine splenocytes and T cells. J Leukoc Biol 65:707–714PubMedGoogle Scholar
  57. Linner KM, Beyer HS, Sharp BM (1991) Induction of the messenger ribonucleic acid for proenkephalin A in cultured murine CD4-positive thymocytes. Endocrinology 128:717–724PubMedGoogle Scholar
  58. Linner KM, Quist HE, Sharp BM (1995) Met-enkephalin-containing peptides encoded by proenkephalin A mRNA expressed in activated murine thymocytes inhibit thymocyte proliferation. J Immunol 154:5049–5060PubMedGoogle Scholar
  59. Mack KJ, Lee MF, Weyhenmeyer JA (1985) Effects of guanyl nucleotides and ions on kappa opioid binding. Brain Res Bull 14:301–306PubMedGoogle Scholar
  60. Madden JJ, Whaley WL, Ketelsen D (1998) Opiate binding sites in the cellular immune system: expression and regulation. J Neuroimmunol 83:57–62PubMedGoogle Scholar
  61. Makman MH, Dvorkin B, Stefano GB (1995) Murine macrophage cell lines contain μ3-opiate receptors. Eur J Pharmacol 273:5–6Google Scholar
  62. McCarthy LE, Nitsche JF, Pintar JE, Rogers TJ (2004) The delta-opioid receptor participates in T-cell development by promoting negative selection. J Neuroimmunol 153:91–98PubMedGoogle Scholar
  63. Mestas J, Hughes CCW (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731–2738PubMedGoogle Scholar
  64. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B et al. (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532–535PubMedGoogle Scholar
  65. Miller B (1996) Delta opioid receptor expression is induced by concanavalin A in CD4+ T cells. J Immunol 157:5324–5328PubMedGoogle Scholar
  66. Negus SS, Dykstra LA (1988) Kappa antagonist properties of buprenorphine in the shock titration procedure. Eur J Pharmacol 56:77–86Google Scholar
  67. Negus SS, Bidlack JM, Mello NK, Furness MK, Rice KC, Brandt MR (2002) Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 13:557–570PubMedGoogle Scholar
  68. Parkhill AL, Bidlack JM (2002) Several δ-opioid receptor ligands display no subtype selectivity to human δ-opioid receptor. Eur J Pharmacol 451:257–264Google Scholar
  69. Parkhill AL, Bidlack JM (2006) Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50, 488 in a mouse monocyte-like cell line. Int Immunopharmacol 6:1013–1019PubMedGoogle Scholar
  70. Paterson SJ, Robson LE, Kosterlitz HW (1986) Control by cations of opioid binding in guinea pig brain membranes. Proc Natl Acad Sci USA 83:6216–6220PubMedGoogle Scholar
  71. Pello OM, Duthey B, Garcia-Bernal D, Rodriguez-Frade JM, Stein JV, Teixido J, Martinez AC, Mellado M (2006) Opioids trigger α5β1 integrin-mediated monocyte adhesion. J Immunol 176:1675–1685PubMedGoogle Scholar
  72. Peluso J, Gaveriaux-Ruff C, Matthes HW, Filliol D, Kieffer BL (2001) Orphanin FQ/nociceptin binds to functionally coupled ORL1 receptors on human immune cell lines and alters peripheral blood mononuclear cell proliferation. Brain Res Bull 54:655–660PubMedGoogle Scholar
  73. Peterson PK, Molitor TW, Chao CC (1998) The opioid–cytokine connection. J Neuroimmunol 83:63–69PubMedGoogle Scholar
  74. Portoghese PS, Larson DL, Sayre LM, Fries DS, Takemori AE (1980) A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem 23:233–234PubMedGoogle Scholar
  75. Portoghese PS, Lipkowski AW, Takemori AE (1987) Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 40:1287–1292PubMedGoogle Scholar
  76. Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol 146:185–186PubMedGoogle Scholar
  77. Rios C, Gomes I, Devi LA (2006) Mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol (in press)Google Scholar
  78. Roy S, Ge BL, Ramakrishan S, Lee NM, Loh HH (1991) [3H]-Morphine binding to thymocytes is enhanced by IL-1 stimulation. FEBS Lett 287:93–96PubMedGoogle Scholar
  79. Roy S, Sedqi M, Ramakrishnan S, Barke RA, Loh HH (1996) Differenctial effects of opioids on the proliferation of a macrophage cell line. Cell Immunol 169:271–277PubMedGoogle Scholar
  80. Royal W, III, Leander MV, Bissonnett R (2005) Retinoid-induced mu opioid receptor expression by phytohemagglutinin-stimulated U937 cells. J Neurovirol 11:157–165PubMedGoogle Scholar
  81. Sedqi M, Roy S, Ramakrishnan S, Elde R, Loh HH (1995) Complementary DNA cloning of a μ-opioid receptor from rat peritoneal macrophages. Biochem Biophys Res Commun 209:563–574PubMedGoogle Scholar
  82. Shavit Y, Lewis JW, Terman GW, Gale RP, Liebeskind JC (1984) Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science 223:188–190Google Scholar
  83. Shahabi NA, Sharp BM (1995) Antiproliferative effects of delta opioids on highly purified CD4(+) and CD8(+) murine T cells. J Pharmacol Exp Ther 273:1105–1113PubMedGoogle Scholar
  84. Shahabi NA, McAllen K, Sharp BM (2003) Phosphorylation of activating transcription factor in murine splenocytes through delta opioid receptors. Cell Immunol 221:122–127PubMedGoogle Scholar
  85. Sharp BM (2003) In: Machelska H, Stein Ch (eds) Immune mechanisms of pain and analgesia. Plenum Publishers, New YorkGoogle Scholar
  86. Sharp BM (2006) Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav Immun 20:9–14PubMedGoogle Scholar
  87. Sharp BM, Keane WF, Suh HJ, Gekker G, Tsukayama D, Peterson PK (1985) Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology 117:793–795PubMedCrossRefGoogle Scholar
  88. Sharp BM, Roy S, Bidlack JM (1998) Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuroimmunol 83:45–56PubMedGoogle Scholar
  89. Sharp BM, Shahabi N, McKean D, Li MD, McAllen K (1997) Detection of basal levels and induction of delta opioid receptor mRNA in murine splenocytes. J Neuroimmunol 78:198–202PubMedGoogle Scholar
  90. Sibinga NES, Goldstein A (1988) Opioid peptides and opioid receptors in cells of the immune system. Annu Rev Immunol 6:219–249PubMedGoogle Scholar
  91. Stefano GB, Cadet P, Scharrer B (1989) Stimulatory effects of opioid neuropeptides on locomotory activity and conformational changes in invertebrate and human immunocytes: evidence for a subtype of delta receptor. Proc Natl Acad Sci USA 86:6307–6311PubMedGoogle Scholar
  92. Stefano GB, Melchiorri P, Negri L, Hughes TK Jr, Scharrer B (1992) [d-Ala2]Deltorphin I binding and pharmacological evidence for a special subtype of delta opioid receptor on human and invertebrate immune cells. Proc Natl Acad Sci USA 89:9316–9320PubMedGoogle Scholar
  93. Sumagin S, Bidlack JM (2005) Delta opioid receptor mRNA expressed in BV-2, a mouse microglial cell line. Society on NeuroImmune Pharmacology Meeting, Clearwater Beach, Florida, April 6–9, 2005Google Scholar
  94. Tosk JM, Grim JR, Kinback KM, Sale EJ, Bozetti LP, Will AD (1993) Modulation of chemiluminescence in a murine macrophage cell line by neuroendocrine hormones. Int J Immunopharmacol 15:615–620PubMedGoogle Scholar
  95. Tubaro E, Borelli G, Croce C, Cavallo G, Santiangeli C (1983) Effect of morphine on resistance to infection. J Infect Dis 148:656–666PubMedGoogle Scholar
  96. VanEpps DE, Saland L (1984) β-Endorphin and met-enkephalin stimulate human peripheral blood mononuclear cell chemotaxis. J Immunol 132:3046–3053Google Scholar
  97. Weber RJ, Pert A (1989) The periaqueductal gray matter mediates opiate-induced immunosuppression. Science 245:188–190PubMedGoogle Scholar
  98. Wei E, Lei P, Liu X, Qian C, Li H, Xia W, Li G (2005) The potential promoter regions on the 5′ flank sequence of the mu opioid receptor gene in lymphocytes. J Cell Biochem 95:1204–1213PubMedGoogle Scholar
  99. Wetzel MA, Steele AD, Eisenstein TK, Adler MW, Henderson EE, Rogers TJ (2000) Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-gamma-inducible protein-10 expression in human peripheral blood mononuclear cells. J Immunol 165:6519–6524PubMedGoogle Scholar
  100. Wick MJ, Minnerath SR, Roy S, Ramakrishnan S, Loh HH (1995) Expression of alternate forms of brain opioid orphan receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines. Mol Brain Res 32:342–347PubMedGoogle Scholar
  101. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, Bell GI (1993) Cloning and functional comparison of κ and δ opioid receptors from mouse brain. Proc Natl Acad Sci USA 90:6736–6740PubMedGoogle Scholar
  102. Zadina JE, Hackler L, Ge LJ, Kastin AJ (1997) A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386:499–502PubMedGoogle Scholar
  103. Zhang L, Rogers TJ (2000) Kappa-opioid regulation of thymocyte IL-7 receptor and C–C chemokine receptor 2 expression. J Immunol 164:5088–5093PubMedGoogle Scholar
  104. Zhang N, Oppenheim JJ (2005) Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. J Leukocyte Biol 78:1210–1214PubMedGoogle Scholar
  105. Zhang N, Rogers TJ, Caterina M, Oppenheim JJ (2004) Proinflammatory chemokines, such as C–C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 173:595–599Google Scholar
  106. Zhu J, Chen C, Xue JC, Kunapuli S, DeRiel JK, Liu-Chen L-Y (1995) Cloning of a human kappa opioid receptor from the brain. Life Sci 56:201–207Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Jean M. Bidlack
    • 1
  • Maxim Khimich
    • 1
  • Amy L. Parkhill
    • 1
  • Sarah Sumagin
    • 1
  • Baoyong Sun
    • 1
  • Christopher M. Tipton
    • 1
  1. 1.Department of Pharmacology and Physiology, School of Medicine and DentistryUniversity of RochesterRochesterUSA

Personalised recommendations